In experimental AD models, semaglutide has been reported to reduce amyloid-beta plaques, attenuate neuroinflammation, and improve cognitive and behavioral deficits 65
diabetes approval anticipated later in 2026 Not yet approved in Canada: but worth knowing about now If you've ever wished the GLP-1 medications that have transformed diabetes care could come in a simple daily pill, without needles, refrigeration, or strict timing around meals, you may be closer to that reality than you think
Co-factor integration with N-acetyl cysteine, vitamin C, and B complex nutrients strengthens multi-pathway absorption, while third-party testing and audit-driven traceability enhance consumer trust
Michelle F
Previously, only those with type 2 diabetes or cardiovascular disease could receive coverage for GLP-1 medications